Study S001156

A Randomised, Double Blind, Parallel Group, Placebo Controlled, Phase 3 Trial of Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT04232969
Acronym: Exenatide-PD3
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 194
Start: 2020-01-20
Primary completion: 2024-02-24
Lead sponsor: University College, London
Conditions: Parkinson's Disease
Interventions: DRUG:Exenatide extended release 2mg (Bydureon)
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 3 [96 weeks]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0020031	Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases. Girges C, Clinical trials (London, England)	2026	Other trial	PMID 41321006 DOI	cites ClinicalTrials.gov:NCT04232969
R0009598	Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Vijiaratnam N, Lancet (London, England)	2025	Randomized trial	PMID 39919773 DOI	cites ClinicalTrials.gov:NCT04232969; registry reference DERIVED:39919773
R0011466	Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study. Vijiaratnam N, BMJ open	2021	Protocol	PMID 34049922 DOI	cites ClinicalTrials.gov:NCT04232969; registry reference DERIVED:34049922
R0036399	Exenatide once a week versus placebo as a potential disease modifying treatment for people with Parkinson’s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial Vijiaratnam N, Newcastle University ePrints (Newcastle Univesity)		Randomized trial		cites ClinicalTrials.gov:NCT04232969